Dihydrofolate reductase inhibitors as antibacterial agents

Biochemical Pharmacology

Volumn 71, Issue 7, 2006, Pages 941-948

  Hawser, Stephen ^a   Lociuro, Sergio ^a   Islam, Khalid ^a  

^a Arpida Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIINFECTIVE AGENT; AR 709; BRODIMOPRIM; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTETROXAZINE; COTRIMAZINE; COTRIMOXAZOLE; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; EPIROPRIM; GLYCOPEPTIDE; ICLAPRIM; ISONIAZID; K 130; MACROLIDE; METICILLIN; OXACILLIN; PENEM DERIVATIVE; PENICILLIN DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFADIAZINE; SULFAFURAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; NONHUMAN; PERITONITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SEPTICEMIA; SKIN INFECTION; URINARY TRACT INFECTION;

EID: 33644508373     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.10.052     Document Type: Article

References (39)

1. F.M. Huennekens In search of dihydrofolate reductase Protein Sci 5 1996 1201 1208
2. G.H. Hitchings, and J.J. Burchall Inhibition of folate biosynthesis and function as a basis for chemotherapy Adv Enzymol Relat Areas 27 1965 417 468
3. G.H. Hitchings, and S.L. Smith Dihydrofolate reductases as targets for inhibitors Adv Enzyme Regul 18 1980 349 371
4. F.M. Sirotnak Folate antagonists as therapeutic agents 1984 John Wiley and Sons New York
5. R.L. Blakley, and S.J. Benkovic Chemistry and biochemistry of folates 1984 John Wiley and Sons New York
6. I.M. Kompis, K. Islam, and R.L. Then DNA and RNA synthesis: antifolates Chem Rev 105 2005 593 620
7. P. Veyssier Inhibiteurs de la dihydrofolate réductase, nitrohétérocycles (furans) et 8-hydroxyquinoléines A. Bryskier Antibiotiques agents antibactériens et antifongiques 1999 Ellipses Paris 995 1029
8. P. Huovinen, L. Sundström, Swedberg Göte, and O. Sköld Trimethoprim and sulfonamide resistance Antimicrob Agents Chemother 39 1995 279 289
9. P.V. Adrian, and K.P. Klugman Mutations in the dihdyrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 41 1997 2406 2413
10. J.P. Maskell, A.M. Sefton, and L.M. Hall Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 1104 1108
11. G.E. Dale, C. Broger, A. D'Arcy, P.G. Hartman, R. DeHoogt, and S. Jolidon A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance J Mol Biol 266 1997 23 30
12. W. Liebenow, and J. Prikryl Structural relationships of new 2,4-diamino-5-benzylpyrimidines J Antimicrob Chemother 5 B 1979 15 28
13. H.A. Salmi, K. Lehtomaki, and T. Kylmamaa Comparison of brodimoprim and doxycycline in acute respiratory tract infections. A double-blind clinical trial Drugs Exp Clin Res 12 1986 349 353
14. P. Periti Evolution of bacterial dihydrofolate reductase inhibitors J Antimicrob Chemother 36 1995 887 890
15. R.L. Then, P.G. Hartman, I. Kompis, M. Stephan-Güuldner, and K. Stöckel Brodimoprim Drugs Future 19 1999 446
16. H.H. Locher, H. Schlunegger, P.G. Hartman, P. Anghern, and R.L. Then Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone Antimicrob Agents Chemother 40 1996 1376 1381
17. A.M. Dhople Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans J Antimicrob Chemother 47 2001 93 96
18. A.M. Dhople In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae Int J Antimicrob Agents 19 2002 71 74
19. R.L. Then Antimicrobial dihydrofolate reductase inhibitors - achievements and future options: review J Chemother 16 2004 3 12
20. P. Wipf, and W. Weiner Enantioselective synthesis and photoracemization studies of (+)-2-cyclopropyl-7,8-dimethoxy-2H-chromene-5-carboxylic acid methyl ester, an advanced intermediate of a dihydrofolate reductase inhibitor J Org Chem 64 1999 5321 5324
21. P.G. Hartman, I. Kompis, J. Jaeger, S. Mukhija, and K. Islam AR-100, a novel diaminopyrimidine, can overcome TMP-resistance in staphylococci and streptococci Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2002 American Society for Microbiology Washington, DC (abstract F-2020)
22. P. Schneider, S. Hawser, and K. Islam Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria Bioorg Med Chem Lett 13 2003 4217 4221
23. S.A. Kohlhoff, P.M. Roblin, T. Reznik, S. Hawser, K. Islam, and M.A. Hammerschlag In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae Antimicrob Agents Chemother 48 2004 1885 1886
24. S. Hawser, L. Weiss, M. Fischer, J. Jaeger, S. Greiveldinger, and D. Gillessen AR-100, a novel diaminopyrimidine compound: bactericidal activity and post-antibiotic effect on Gram-positive pathogens Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2002 American Society for Microbiology Washington, DC (abstract F-2029)
25. L. Weiss, D. Gillessen, S. Hawser, and K. Islam Iclaprim, a novel diaminopyrimidine antibiotic: synergy studies with different classes of antibiotics Proceedings of the 14th European Congress of Clinical Microbiology and Infectious Diseases 2004 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (abstract 902)
26. M.E. Jones, J.A. Karlowsky, D.C. Draghi, C. Thornsberry, D.F. Sahm, and D. Nathwani Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy Int J Antimicrob Agents 22 2003 406 419
27. S. Hawser, A. Haldimann, S. Parisi, D. Gillessen, and K. Islam AR-100, a novel diaminopyrimidine compound: resistance studies in trimethoprim-sensitive and -resistant Staphylococcus aureus Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2002 American Society for Microbiology Washington, DC (abstract F-2028)
28. D. Krievens, A. Leighton, R. Brandt, P. Hadvary, S. Hawser, and D. Gillessen Efficacy and safety of intravenous Iclaprim in complicated skin and skin structure infections: results of a phase 2 study Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2005 American Society for Microbiology Washington, DC (abstract L-1579)
29. J.M. Andrews, D. Honeyboune, J.P. Ashby, G.M. Jevons, A.P. Fraise, and P. Fry Concentrations of Iclaprim in plasma, epithelial lining fluid (ELF), alveolar macrophages (AM) and bronchial mucosa (BM) following a single 1.6 mg/kg intravenous infusion in healthy subjects Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2005 American Society for Microbiology Washington, DC (abstract A-9)
30. Arpida company website, http://www.arpida.ch.
31. A.K. Debnath Pharmacophore mapping of a series of 2,4-diamino-5- deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase J Med Chem 45 2002 41 53
32. M. Graffner-Nordberg, K. Kolmodin, J. Aqvist, S.F. Queener, and A. Hallberg Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii J Med Chem 44 2001 2391 2402
33. D.C. Chan, C.A. Laughton, S.F. Queener, and M.F. Stevens Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase J Med Chem 44 2001 2555 2564
34. A.B. Gerum, J.E. Ulmer, D.P. Jacobus, N.P. Jensen, D.R. Sherman, and C.H. Sibley Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase Antimicrob Agents Chemother 46 2002 3362 3369
35. A.M. Dhople In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae Arzneim Forsch/Drug Res 49 1999 267 271
36. W.J. Suling, and J.A. Maddry Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium avium complex in vitro J Antimicrob Chemother 47 2001 451 454
37. W.J. Suling, L.E. Seitz, V. Pathak, L. Westbrook, E.W. Barrow, and S. Zywno-Van-Ginkel Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase Antimicrob Agents Chemother 44 2000 2784 2793
38. I.O. Donkor, H. Li, and S.F. Queener Synthesis and DHFR inhibitory activity of a series of 6-substituted-2,4-diaminothieno[2,3-d]pyrimidines Eur J Med Chem 38 2003 605 611
39. E.W. Barrow, J. Dreier, and W.W. Barrow Selective inhibitors for anthrax Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2005 American Society for Microbiology Washington, DC (abstract F-2072)